Latest Conference Articles

March 12th 2017, 1:02am

PER® Miami Breast Cancer Conference

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for a patient with early-stage breast cancer.

March 11th 2017, 10:59pm

PER® Miami Breast Cancer Conference

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

March 11th 2017, 7:15pm

PER® Miami Breast Cancer Conference

Healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer, indicating a need for better targeted treatments for this patient class.

March 11th 2017, 2:35am

PER® Miami Breast Cancer Conference

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

March 11th 2017, 1:46am

PER® Miami Breast Cancer Conference

Adding CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer, William J, Gradishar, MD, explained in a presentation at the 34th Annual Miami Breast Cancer Conference.

March 11th 2017, 1:07am

PER® Miami Breast Cancer Conference

The so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

March 10th 2017, 10:44pm

PER® Miami Breast Cancer Conference

It is imperative that surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer, given a shortage of available genetic counselors.

March 10th 2017, 9:53pm

PER® Miami Breast Cancer Conference

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.

March 10th 2017, 5:05am

PER® Miami Breast Cancer Conference

Adding ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to a subgroup analysis of the phase III MONALEESA-2 trial presented at the 34th Annual Miami Breast Cancer Conference.

March 10th 2017, 4:57am

PER® Miami Breast Cancer Conference

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the APHINITY and ExteNET studies in breast cancer.

March 10th 2017, 4:53am

PER® Miami Breast Cancer Conference

The combination of eribulin and pembrolizumab demonstrated promising objective response rates, including a complete response, for patients with metastatic triple-negative breast cancer.

March 10th 2017, 1:42am

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

February 27th 2017, 5:08am

Transplantation and Cellular Therapy Meetings

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

February 27th 2017, 1:36am

Transplantation and Cellular Therapy Meetings

Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.

February 26th 2017, 11:32pm

Transplantation and Cellular Therapy Meetings

Vorinostat combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant.

February 26th 2017, 11:13pm

Transplantation and Cellular Therapy Meetings

Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.

February 26th 2017, 10:30pm

Transplantation and Cellular Therapy Meetings

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

February 26th 2017, 5:10am

Transplantation and Cellular Therapy Meetings

A host of new and emerging therapies for acute and chronic graft-versus-host disease are on the horizon and include B-cell depletion, IL-2, inhibitors of JAK1/JAK2, extracorporeal photopheresis, and the BTK inhibitor ibrutinib.

February 26th 2017, 3:53am

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, reviewed emerging strategies to improve stem cell transplantation outcomes by reducing the risk of relapse using novel drugs and targeted radiotherapy.

February 26th 2017, 3:43am

Transplantation and Cellular Therapy Meetings

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.